Novartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg Reinhardt
(Thomson Reuters ONE) -
Novartis International AG /
Novartis Foundation confirms new members of its Board of trustees, including new
Chairman Dr. Joerg Reinhardt
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Dr. Joerg Reinhardt, Chairman of the Novartis Board of Directors, will serve
as Chairman of the Foundation Board of trustees
* New trustees also include Professor Peter Piot of the London School of
Hygiene & Tropical Medicine, Dr. Rebecca Weintraub of Harvard Medical
School, and Mr. Rainer Boehm from Novartis Pharmaceuticals
* The Novartis Foundation and its partners are pioneering innovative
healthcare models to have a transformational impact on the health of the
poorest populations
Basel, July 27, 2015 - The Novartis Foundation announces four new members of its
Board of trustees, including Dr. Joerg Reinhardt, who succeeds Dr. Andrin Oswald
as Chairman of the Novartis Foundation. Prof. Peter Piot of the London School of
Hygiene & Tropical Medicine and Dr. Rebecca Weintraub of Harvard Medical School
join the board along with Mr. Rainer Boehm from Novartis Pharmaceuticals.
Mr. Juergen Brokatzky-Geiger, Global Head of Corporate Responsibility for
Novartis, and Dr. Ann Aerts, Head of the Novartis Foundation, will remain on the
Novartis Foundation Board. Previous Board members Mr. George Gunn and Prof. Dr.
Jean-Marie Lehn stepped down in the past year.
"The Novartis Foundation has been committed to improving healthcare for the
poorest populations for more than 35 years," said Dr. Joerg Reinhardt, Chairman
of the Novartis Board of Directors. "I am happy to contribute to the
continuation of this important work and to welcome two external board members
who bring a wealth of experience and expertise in Global Health as well as a
fresh perspective on the Novartis Foundation."
Rebecca Weintraub, MD, is an Assistant Professor of Medicine at Harvard Medical
School, an Associate Physician in the Division of Global Health Equity at
Brigham and Women's Hospital and Faculty Director of the Global Health Delivery
Project at Harvard University. Peter Piot, MD, PhD, is currently the Director of
the London School of Hygiene & Tropical Medicine. Formerly, he was the founding
Executive Director of UNAIDS and he is the co-discoverer of the Ebola virus.
"We are at a crucial point in global health. In low- and middle-income countries
we still struggle with managing infectious disease, maternal and child health
and malnutrition, while at the same time, there is a growing crisis of non-
communicable diseases such as heart disease and diabetes. There is also the
emergence of technology and connectivity that allows us to reach patients and
healthcare professionals more than ever before," said Professor Peter Piot. "I
am excited to be part of the Novartis Foundation team working with the global
health community to innovate healthcare delivery addressing this double burden
of disease to improve the health of people in these geographies and to empower
their communities and governments to sustain improved health services for the
long term."
The Novartis Foundation is a philanthropic organization pioneering innovative
healthcare models that can have a transformational impact on the health of the
poorest populations. We work hand-in-hand with our local and global partners to
accelerate elimination of leprosy and malaria by focusing on interventions that
aim to interrupt transmission, and to catalyze scalable and sustainable
healthcare models to improve access and health outcomes. Everything we do is
grounded in evidence and innovation, and our work is a continuous cycle of
evaluation, adaptation and application. In 2014, the operational budget for the
foundation was CHF 12 million and our programs reached 3.6 million people.
Disclaimer
This press release contains expressed or implied forward-looking statements,
including statements that can be identified by terminology such as "will,"
"committed," "to improve," "to empower," "can," "to accelerate," "to improve,"
or similar expressions. Such forward-looking statements reflect the current
views of the Group regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be materially
different from any future results expressed or implied by such statements. These
expectations could be affected by, among other things, risks and factors
referred to in the Risk Factors section of Novartis AG's current Form 20-F on
file with the US Securities and Exchange Commission. Novartis is providing the
information in this press release as of this date and does not undertake any
obligation to update it in the future.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2014, the Group achieved net
sales of USD 58.0 billion, while R&D throughout the Group amounted to
approximately USD 9.9 billion (USD 9.6 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 120,000
full-time-equivalent associates and sell products in more than 180 countries
around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Julie Morrow
Novartis Global Media Relations Novartis Foundation
+41 61 324 7999 (direct) +41 61 696 2421 (direct)
+41 79 593 4202 (mobile) +41 79 224 5666 (mobile)
eric.althoff(at)novartis.com julie.morrow(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448
Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1941270/701568.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
[HUG#1941270]
Unternehmensinformation / Kurzprofil:
Datum: 27.07.2015 - 07:16 Uhr
Sprache: Deutsch
News-ID 409147
Anzahl Zeichen: 8278
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 218 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg Reinhardt"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
